DLA Piper’s Dick Armey and the Lobbying Business

The Times reports on the fate of DLA Piper’s Dick Armey in “Drug Firms Cost Lobbyist His Position.”

To review the facts of this case: the drug companies who helped defeat the Clinton administration health care effort 15 years ago have now turned on Mr. Armey, who then was one of their most important Congressional allies. Now, having cut a deal with this administration to limit their share of the costs, the drug companies are on the other side. Foreseeing new profits from the expansion of health coverage, they are spending as much as $150 million on advertisements to support the president’s plan.

Comments are closed.